

Amendments to the Specification

Please replace page 88 of the specification with the rewritten version thereof that appears on the following page.

Table 1, cont.

Composition -	drug (mg/mL)	20-30	drug (mg/mL)	20-30	NA
Prelipophilate	Acid (Molar)	1.4	Acid (Molar)	1.4	
	Antioxidant (mg/mL)	0-10	Antioxidant (mg/mL)	0-10	
	Captisol (mg/mL)	200-300	Filler (mg/mL)	20-30	
	Water for Injection. qs to 1.0 mL		Polysorbate-80(mg)	0-50	
	pH	1.5-2.0	Water for Injection. qs to 1.0 mL		
			pH	1.5-2.0	

Acids used: Methane sulfonic acid, Tartaric acid, Citric acid, succinic acid is used in a 1:1:4 molar ratio for in-situ salt formation.

Cosolvents- PEG-300, PEG-400:

Surfactants: Polysorbate-80, Cremophor EL

Captisol®: Sulfobutylether Cyclodextrin

Drug: Compound of Example 2

Please replace the paragraph at page 89, lines 7-13 with the following rewritten version thereof:

The present invention is not to be limited in scope by the exemplified embodiments which are intended as illustrations of single aspects of the invention, ~~and any clones, DNA or amino acid sequences which are functionally equivalent are within the scope of the invention.~~ Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description ~~and accompanying drawings.~~ Such modifications are intended to fall within the scope of the appended claims.